Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 260 participants.
Also called NCT04240444
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 260 participants
- Registry
-
NCT04240444
-
- Other papers using this trial's data
- Sirolimus- vs Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis: The SIBLINT-ISR Randomized Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04240444. Randomized; single masking; primary purpose treatment. Start 2020-10-10 (actual); primary completion 2022-07-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sirolimus-Coated Balloon Versus Paclitaxel-Coated Balloon for the Treatment of Coronary In-Stent Restenosis
- Acronym
- SIBLINT ISR
- Condition
- Coronary Artery Disease
- Condition
- In Stent Restenosis
- Intervention (Device)
- drug-coated balloon Catheter
- Lead sponsor
- B. Braun Medical International Trading Company Ltd.
- Collaborator
- CCRF Inc., Beijing, China
Record details
- Record id
cardio:ct-nct04240444- Content hash
8e2c98b0fd96108a7f1d46101ffb16751e217ae2fd63147e58ce3fdf0914ccfe